Venture-Ready Technologies are some of the University of Rochester’s most promising inventions. We believe the technologies and innovations described below have significant commercial potential. Some of these items could fit nicely into a company’s existing intellectual property portfolio to enhance a product line or help launch a new one. Others represent platform technologies that could constitute the foundation of a new startup company. In either case, we invite you to peruse the following which will be updated periodically with new featured patents. If anything is of interest, please contact UR Ventures.
A live-attenuated vaccine for canine influenza virus.
A novel vaccine against Type I Diabetes
A biomarker to save time and money in the treatment of arthritis.
A method to enhance the effects of deep brain stimulation.
A safe and effective therapy based on the bacterial AvrA peptide for the treatment of inflammatory bowel and celiac diseases.
A vaccine effective against all four strains of the Dengue virus.
A method to suppress premature stop codons in order to generate full-length mRNA using target-specific guide mRNAs.
A protein/peptide-based therapy for the prevention and treatment of obesity with desirable side effect profile.
A method of remyelinating axons using oligodendrocyte progenitor cells.
A novel method for treating and preventing dental diseases.
A novel synthetic lung surfactant for the treatment of neonatal and acute respiratory distress syndromes.
Methods for obtaining specific and non-toxic inhibitors of Activation Induced Deaminase nuclear import that prevent the progression of follicular lymphoma, once diagnosed.
A human Biliverdin Reductase-based peptide therapy for the treatment of diabetes.
A novel method for treating and preventing fibrosis and fibrosis-related conditions using fibronectin binding proteins and polypeptides.
A novel therapy method for delivering localized anti-cancer responses without adverse body-wide side effects.
A novel therapy using light-activated chemokine receptors to direct specific lymphocytes to desired locations within a patient’s body.
A novel protocol to produce large quantities of nearly 100% homogenous heavy-labeled acyl-CoAs rapidly and inexpensively.
Small compounds that inhibit the uptake of amyloid-β into the brain.
A new cell therapy for treating damage to the central nervous system.
A treatment for hyperammonemic Encephalopathy and Seizures.
A safe and effective treatment for Rheumatoid Arthritis using approved drugs.
A simple and robust in vitro DNA-based diagnostic assay to aid in determining the prognosis of patients with chronic lymphocytic leukemia (CLL).
A safer and more effective nasal vaccine against influenza.
A novel strategy for developing safe and effective live-attenuated arenavirus vaccines.
Compounds that can induce melanin expression to aid in certain clinical indications or for cosmetic purposes.
Methods for the protection, repair, and regeneration of articular cartilage and fibrocartilaginous tissues using recombinant parathyroid hormones.
An RNA therapeutic approach based on a “tailor-made” mRNA splice factor to treat genetic diseases that are caused by mRNA splice site mutations, such as muscular dystrophy, β-thalassemia, retinitis pigmentosa, neurofibromatosis, and cancers.